Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genetic Technologies' BrevaGen

This article was originally published in The Gray Sheet

Executive Summary

Breast cancer risk test is acquired through an asset purchase deal with Perlegen Sciences for undisclosed terms. Announced April 14, the deal will allow Genetic Technologies to launch the test in the U.S. and Australia in the second half of 2010, the firm says. The test combines population risk factors based on the Gail Score with validated genetic risk factors to measure non-familial, sporadic risk of breast cancer for women where a breast biopsy outcome is indeterminate, the company explains. "This product fulfils an unmet need by better classifying women at moderate risk of breast cancer who would potentially benefit from preventive therapy or more intensive monitoring." The firm estimates the potential U.S. market at up to $400 million-$500 million
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT028759

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel